Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021-Reference-Cited by-同舟云学术

Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021

Published:2022-05-26 Issue:7 Volume:31 Page:693-706
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Brown Zachary J.¹,Hewitt D. Brock²,Pawlik Timothy M.¹²

Affiliation:

1. Department of Internal Medicine, The Ohio State University Wexner Medical Center The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA

2. Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2079491

Reference139 articles.

1. Hepatocellular carcinoma

2. Hepatocellular carcinoma

3. Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma

4. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a dual-target DYRK2 and HDAC8 inhibitor for the treatment of hepatocellular carcinoma;Biomedicine & Pharmacotherapy;2024-08

2. Top Hepatobiliary Articles from 2022 to Inform Your Cancer Practice;Annals of Surgical Oncology;2023-10-16

3. HIF‑1α and RACGAP1 promote the progression of hepatocellular carcinoma in a mutually regulatory way;Molecular Medicine Reports;2023-09-27